Search | Clinical Trials Finder

Conditions: Metastatic Breast Cancer
Interventions: Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 22 more

Conditions: Upper Extremity Paresis, Stroke, Chronic
Interventions: NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), Upper Limb Rehabilitation, Sham Stimulation; Device · Other
Lead sponsor: NeuraStasis, Inc; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spinal Cord Injuries
Interventions: Heated Vest, Non-Heated Vest; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 68 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Families Experiencing Homelessness and/or Housing Instability, Housing Stability
Interventions: Guaranteed Income, Public Benefits Information Session; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: San Jose, California

Conditions: Early Rheumatoid Arthritis
Interventions: Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 31
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more

Conditions: Cancer, Cancer, Treatment-Related, Medication Adherence, Communication, Tyrosine Kinase Inhibitor
Interventions: Oncotool Intervention (symptom reporting + TKI education), Oncotool Control (health information); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer Disease, Dementia, Gamification, Assistive Technology
Interventions: The MapHabit system (MHS); Device
Lead sponsor: MapHabit, Inc.; Industry
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions: Pomalidomide 0.5 mg, Placebo, Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: Stroke, Stroke, Acute, Balance; Distorted, Balance; Impairment, Gait, Unsteady
Interventions: Body weight support system control group, Body weight support system with balance perturbations; Device
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Wallingford, Connecticut • Washington D.C., District of Columbia • Sandwich, Massachusetts + 1 more

Conditions: Acromegaly
Interventions: ONO-5788, ONO-5788 Placebo, Octreotide; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Acne Vulgaris
Interventions: CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more

Conditions: Sickle Cell Disease
Interventions: PCV21, 20vPCV; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more

Conditions: Pain, Postoperative
Interventions: Control Group - ESP block with SAP block, Treatment Group - ESP block with SAP normal saline; Drug
Lead sponsor: Anna Uskova; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Yellow Fever, Yellow Fever Immunisation
Interventions: ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa • St Louis, Missouri

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Risankizumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 44
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more

Conditions: Healthy Adult Male, Healthy Adult Females, Joint Discomfort
Interventions: Olive Oil Extract, Placebo; Dietary Supplement
Lead sponsor: Applied Food Sciences Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes Mellitus
Interventions: 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea; Drug · Other
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more

Conditions: Obsessive Compulsive Disorder
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Hartford Hospital; Other
Eligibility: 20 Years to 60 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Melanoma, UV Ray Skin Damage
Interventions: Standard Sunscreen, BNP; Drug · Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Ankle Instability
Interventions: Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION), Evidence-Based; Other
Lead sponsor: Womack Army Medical Center; Federal
Eligibility: 18 Years to 44 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Lexington, Kentucky • Fort Bragg, North Carolina

Conditions: Covid19, Critical Illness, High Intensity Interval Training, ICU, Intensive Care Units, Fitness Trackers
Interventions: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT), Comparator; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Nashville, Tennessee

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801; Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Heart Failure
Interventions: Remote monitoring and predictive analytics, Sham comparator; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Palo Alto, California • Gainesville, Florida • Salt Lake City, Utah + 1 more

Conditions: Skin Diseases, Infectious
Interventions: sterile Phosphate Buffer Saline, SGW13; Other
Lead sponsor: Center for Innovation and Research Organization; Network
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits

Heated Vest for Persons With Spinal Cord Injury

Silicon Valley Guaranteed Income Project

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Oncotool for Cancer Medications

Efficacy of Gamification in Enhancing User Engagement

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

A Multisite Exploration of Balance Perturbations With and Without Body Weight Support

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

Erector Spinae Plane Block vs Erector Spinae Plane Block With Serratus Anterior Plane Block in Thoracic Surgery

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Examining Olive Oil Extract on Knee Comfort and Function

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Neural Mechanisms of CBT Response in Hoarding Disorder

A Sunscreen Based on Bioadhesive Nanoparticles

Neurocognitive Ankle Training for Instability to Optimize Neuromusculoskeletal Outcomes (NATION)

REmotely Monitored, Mobile Health-Supported High Intensity Interval Training After COVID-19 Critical Illness (REMM-HIIT-COVID-19)

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

LINK-HF2 - Remote Monitoring Analytics in Heart Failure

Effect of an Antiseptic Solution on the Skin Microbiome